Drug developer Appili Therapeutics nets $2.15 mln in follow-on VC
Halifax drug development startup Appili Therapeutics Inc has raised $2.15 million in a follow-on round. New and existing investors backed the deal, including Canadian venture capital firm Innovacorp and others that joined the company's $3.27 million seed financing in May. Founded last year with the support of Bloom Burton & Co, Appili is a developer of novel therapeutics for infectious diseases. It will use the latest funds raised to advance the company's lead product candidate, an antibiotic designed to treat anaerobic infections, into clinical trials. Appili also plans to add to its anti-infective pipeline.
22 December 2016•3 mins read
